A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates for patients with refractory CD30-positive lymphomas, according to a new study from The University of Texas MD Anderson Cancer Center.
Results from the Phase I trial, published today in Nature Medicine, demonstrated an overall response rate of 92.9% and a complete response of 66.7% in 42 heavily…
Continue Reading
News Source: www.sciencedaily.com
Leave a Reply